Protalix BioTherapeutics CEO Outlines Strategic Priorities for 2026 and Progress in Clinical Pipeline

Protalix BioTherapeutics (NYSE‑A: PLX) has published a letter from its CEO, Dror Bashan, detailing the company’s strategic direction for 2026, emphasizing advancement of its clinical pipeline and strengthening its commercial partnerships. In the letter to shareholders, Bashan reiterated Protalix’s commitment to building a profitable business with innovative treatments for patients with rare and high‑need diseases. A major focus for the company is PRX‑115, an investigational therapy for uncontrolled gout. According to Bashan, Phase 1 data showed that PRX‑115 achieved a rapid and durable reduction in urate levels with a good tolerability profile, positioning it as a differentiated treatment option. With global gout cases rising and unmet needs persisting, Protalix plans a Phase 2 trial following US FDA clearance of its investigational new drug application. Protalix is also expanding its rare kidney disease research with PRX‑119, a long‑acting DNase I therapeutic designed to reduce inflammation and fibrosis. Commercially, the company continues to execute with partner Chiesi Global Rare Diseases after the launch of Elfabrio for Fabry disease, which remains its main revenue driver, while addressing regulatory developments in Europe. Collaborations involving Elelyso with Pfizer and Brazil’s Fundação Oswaldo Cruz are expected to contribute further. #ProtalixBioTherapeutics #ClinicalPipeline #RareDisease #BiotechNews #SlimScan #GrowthStocks #CANSLIM